PD 117302

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 525823

CAS#: 111728-01-9

Description: PD 117302 a new nonpeptide opioid compound shown in in vitro studies to be a selective kappa-opioid agonist, has been evaluated in vivo for antinociceptive activity and other effects characteristic of kappa-receptor activation. PD 117302 also causes naloxone-reversible locomotor impairment and diuresis, effects that are typical of kappa-agonists. It is an Anti-Arrhythmia Agent, an Anticonvulsants, a Cardiovascular Agent, and a Central Nervous System Agent.

Chemical Structure

img
PD 117302
CAS# 111728-01-9
Instruction

Theoretical Analysis

MedKoo Cat#: 525823
Name: PD 117302
CAS#: 111728-01-9
Chemical Formula: C21H28N2OS
Exact Mass: 356.19
Molecular Weight: 356.525
Elemental Analysis: C, 70.75; H, 7.92; N, 7.86; O, 4.49; S, 8.99

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: PD117302; PD-117302; PD 117302

IUPAC/Chemical Name: 2-(benzo[b]thiophen-4-yl)-N-methyl-N-((1R,2R)-2-(pyrrolidin-1-yl)cyclohexyl)acetamide

InChi Key: SYHJZCCNQDFHJQ-RTBURBONSA-N

InChi Code: InChI=1S/C21H28N2OS/c1-22(18-8-2-3-9-19(18)23-12-4-5-13-23)21(24)15-16-7-6-10-20-17(16)11-14-25-20/h6-7,10-11,14,18-19H,2-5,8-9,12-13,15H2,1H3/t18-,19-/m1/s1

SMILES Code: O=C(N(C)[C@H]1[C@H](N2CCCC2)CCCC1)CC3=C(C=CS4)C4=CC=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 356.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Leighton GE, Hill RG, Hughes J. The effects of the kappa agonist PD-117302 on feeding behaviour in obese and lean Zucker rats. Pharmacol Biochem Behav. 1988 Oct;31(2):425-9. PubMed PMID: 2854265.
2: Leighton GE, Johnson MA, Meecham KG, Hill RG, Hughes J. Pharmacological profile of PD 117302, a selective kappa-opioid agonist. Br J Pharmacol. 1987 Dec;92(4):915-22. PubMed PMID: 2827830; PubMed Central PMCID: PMC1853714.
3: Colombo M, Petrillo P, La Regina A, Bianchi G, Tavani A. In vitro binding profile and in vivo pharmacological properties of the K-opioid compound PD 117302. Res Commun Chem Pathol Pharmacol. 1991 Jun;72(3):295-306. PubMed PMID: 1658887.
4: Porreca F, Ianone M, Wheeler H, Cowan A. Comparison of PD 117302, a kappa agonist, and morphine on colonic transit and formalin-induced pain in rats. Proc West Pharmacol Soc. 1989;32:185-7. PubMed PMID: 2550944.
5: Pugsley MK, Saint DA, Hayes ES, Abraham S, Walker MJ. An examination of the cardiac actions of PD117,302, a κ-opioid receptor agonist. Eur J Pharmacol. 2015 Aug 15;761:330-40. doi: 10.1016/j.ejphar.2015.06.018. Epub 2015 Jun 15. PubMed PMID: 26086860.
6: Moussaoui SM, Montier F, Carruette A, Blanchard JC, Laduron PM, Garret C. A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically. Br J Pharmacol. 1993 May;109(1):259-64. PubMed PMID: 7684305; PubMed Central PMCID: PMC2175579.
7: Parrott RF, Ebenezer IS, Baldwin BA, Forsling ML. Hormonal effects of apomorphine and cholecystokinin in pigs: modification of the response to cholecystokinin by a dopamine antagonist (metoclopramide) and a kappa opioid agonist (PD117302). Acta Endocrinol (Copenh). 1991 Oct;125(4):420-6. PubMed PMID: 1957561.
8: Shukla VK, Turndorf H, Bansinath M. Pertussis and cholera toxins modulate kappa-opioid receptor agonists-induced hypothermia and gut inhibition. Eur J Pharmacol. 1995 Mar 16;292(3-4):293-9. PubMed PMID: 7796869.
9: Wheeler-Aceto H, Cowan A. Standardization of the rat paw formalin test for the evaluation of analgesics. Psychopharmacology (Berl). 1991;104(1):35-44. PubMed PMID: 1882002.
10: Leighton GE, Hill RG, Hughes J. Effects of 5-HT and alpha 1 adrenoceptor antagonists on kappa opioid-induced sedation. Pharmacol Biochem Behav. 1988 Dec;31(4):899-904. PubMed PMID: 2855271.
11: Bansinath M, Ramabadran K, Turndorf H, Shukla VK. Intracerebroventricular administration of kappa-agonists induces convulsions in mice. Brain Res Bull. 1991 Jul;27(1):75-9. PubMed PMID: 1657321.
12: Nemmani KV, Gullapalli S, Ramarao P. Potentiation of kappa-opioid receptor agonist-induced analgesia and hypothermia by fluoxetine. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):189-93. PubMed PMID: 11420085.
13: Petrillo P, Kowalski J, Sbacchi M, Tavani A. Characterization of opioid binding sites in rat spinal cord. J Recept Res. 1992;12(1):39-57. PubMed PMID: 1314311.
14: Agbas A, Simon J, Avni Oktem H, Varga E, Borsodi A. Characterization of human placental opioid receptors by 3H-ethylketocyclazocine and 3H-naloxone binding. Neuropeptides. 1988 Oct;12(3):171-6. PubMed PMID: 2907370.
15: Carey GJ, Bergman J. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists. J Pharmacol Exp Ther. 2001 Apr;297(1):215-23. PubMed PMID: 11259547.
16: Wilson JL, Walker JS, Antoon JS, Perry MA. Intercellular adhesion molecule-1 expression in adjuvant arthritis in rats: inhibition by kappa-opioid agonist but not by NSAID. J Rheumatol. 1998 Mar;25(3):499-505. PubMed PMID: 9517771.
17: Bansinath M, Ramabadran K, Turndorf H, Puig MM. Kappa-opiate agonist-induced inhibition of gastrointestinal transit in different strains of mice. Pharmacology. 1991;42(2):97-102. PubMed PMID: 1648236.
18: Gué M, Alvinerie M, Junien JL, Buéno L. Stimulation of kappa opiate receptors in intestinal wall affects stress-induced increase of plasma cortisol in dogs. Brain Res. 1989 Nov 13;502(1):143-8. PubMed PMID: 2555024.
19: Ribeiro W, Ifa DR, Corso G, Salmon J, Moraes LA, Eberlin MN, de Nucci G. Determination of RSD921 in human plasma by high-performance liquid chromatography-tandem mass spectrometry using tri-deuterated RSD921 as internal standard: application to a phase I clinical trial. J Mass Spectrom. 2001 Oct;36(10):1133-9. PubMed PMID: 11747107.
20: Sheridan RD. Quantification of state-dependent drug interactions with the sodium channel. Br J Pharmacol. 2000 Jan;129(2):409-11. PubMed PMID: 10694250; PubMed Central PMCID: PMC1571825.